Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Encourages trials of anti-inflammatory or lipid therapies in aortic stenosis; leaves open whether they modify progression or outcomes.
Calcific valve disease represents a disease spectrum that ranges from mild irregular valve thickening (or sclerosis) to severe valve obstruction Over the past decade, our concept of the pathogenesis of calcific aortic valve disease has undergone a major transformation. We now recognise that calcific valve disease is the end stage of an active disease process and is not caused by “wear and tear” of the valve tissue. Immunohistochemical studies of trileaflet aortic valves with varying degrees of valve stenosis have demonstrated the presence of inflammation, lipid infiltration, and production of proteins that mediate tissue calcification. These studies have established the presence of T lymphocytes and macrophages both in the early stages of this disease process and in valves with severe stenosis removed at surgery.1,2 The inflammatory cell infiltrate is located in areas of subendothelial lipid infiltration on the aortic side of the valve leaflet with extension into the adjacent fibrosa, the dense collagenous layer of the leaflet that provides tensile strength. The focal presence of neutral lipid can be demonstrated with oil-red-O staining with specific immunohistochemical markers being consistent with infiltration of low density lipoprotein and lipoprotein Lp(a). In addition, there is evidence of lipid oxidation, as is seen in atherosclerotic …
No takes yet. Share an insight, caveat, or question.
Catherine M Otto (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: